Significance of FDP levels in serum and plasma measured by anti-FgDPneo antibody

Abstract

Plasma and serum FDP levels in various malignant diseasez wers measured by RIA using anti-FgDP (FgE)neo antibody and following results were obtain.Anti-FgDPneo antibody, purified by affinity chromatography to remove antifibrinogen activity, did not show any cross-reactivity with fibrinogen, but showed apparent cross-reaction to early products revealed by inhibition curves of double antibody method (RIA).The result indicated that FgDPneo antigen is exposed at early stage of fibrinogen degradation process. This antibody reacted with fibrin degradation products as well as fibrinogen degradation products.In most of patients with malignancy, high level of FDP was detected in both plasma and serum. Some of them had elevated levels of FDP in plasma with normal levels in serum. This discrepancy was assumed to be due to the increased early (clottable) products of fibrinogen or fibrin in plasma which was removed in serum.Thus, it was considered that patients with malignancy generally have elevated levels of FDP in plasma regardless of serum levels, and this hyper-FDP levels in plasma may well be related to the latent fibrinolitic activity in blood.